PDX models move into radiopharma preclinical testing
Perceptive Discovery and Certis Oncology will combine patient-derived xenograft tumor models with radiochemistry, imaging, pharmacology, and quantitative analysis capabilities.
Perceptive Discovery and Certis Oncology have formed a strategic collaboration to support preclinical radiopharmaceutical development.
The agreement gives Perceptive Discovery access to Certis Oncology’s study-ready in vivo patient-derived xenograft models. The models span multiple tumor types and molecular profiles.
Certis Oncology’s PDX models will be incorporated into Perceptive Discovery’s preclinical workflows for targeted radiotherapeutics and radiotracers.
The collaboration covers in vitro characterization, in vivo imaging, biodistribution, and efficacy assessment. It also includes molecularly characterized oncology models for target-specific and indication-focused development strategies.
Perceptive Discovery brings radiochemistry, multimodal imaging, in vitro and in vivo pharmacology, and quantitative image analysis capabilities to the collaboration.
Certis Oncology describes its platform as combining predictive modeling, multimodal datasets, and functional validation in patient-derived cancer models. The company operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in San Diego.
The companies said the collaboration is designed to generate decision-ready preclinical datasets for radiopharmaceutical sponsors, including exploratory, translational, and IND-enabling research programs.
Companies:Perceptive Discovery, Certis Oncology
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Telix, United Imaging explore U.S. theranostics research
Telix and United Imaging Healthcare North America will evaluate a U.S. research collaboration focused on scanner, software, AI, and radiopharmaceutical workflow integration.
Subtle Medical raises $33M for AI imaging expansion
The Series C-backed growth capital brings Subtle Medical’s total funding to $86M as the company scales its vendor-neutral AI imaging platform across MRI, PET, and CT.
contextflow deal gives 4DMedical a European lung CT base
The binding agreement would add a Vienna-based team, a CE-marked chest CT product suite, German reimbursement contracts, and a route for CT expansion in Europe.
uMI Panvivo Mobile joins United Imaging PET lineup
United Imaging used SNMMI 2026 to show new PET/CT and PET/MR systems, including uMI Panvivo Mobile, uMI Panorama GS, and uPMR Zenith.
Idaho Falls site added to RTX-2358 manufacturing plan
PharmaLogic will expand production capacity for Ratio Therapeutics’ Ac-225 RTX-2358 as the FAP-targeted radiopharmaceutical moves through ATLAS clinical testing.
Ilumira authorization opens EU route for SHINE Lu-177
The EMA-authorized radiopharmaceutical precursor is produced at SHINE’s Cassiopeia facility in Wisconsin for use in radiolabelling carrier medicines.
Virginia theranostics program takes shape with Sentara-BAMF
The joint venture is intended to combine radiopharmaceutical production, molecular imaging, molecular therapy, and clinical trials in a vertically integrated model.
Lead-212 supply pact links Eckert & Ziegler, Thor Medical
hor Medical will initially supply Pb-212 to Eckert & Ziegler for preclinical R&D, while the companies explore broader isotope-production and radiopharmaceutical-manufacturing integration.
Aidoc creates growth post for enterprise AI push
Christopher Young will lead global expansion, partnerships, and enterprise growth after prior healthcare technology roles at BCG and Ascension.
Everlight shifts global teleradiology stack to RadOS
The 5-year agreement will put Sirona Medical’s cloud-native platform across Everlight’s operations in 6 markets, covering PACS, reporting, worklist, archive, and AI workflows.
HCA’s CHCP deal includes imaging CE provider MTMI
HCA Healthcare agreed to acquire CHCP, a Texas allied-health education provider that owns MTMI and offers programs in sonography, radiologic technology, and medical coding.
CBCT perfusion collaboration targets stroke angio suite
Siemens Healthineers and Cercare Medical are pairing Syngo DynaCT Multiphase with Neurosuite to support perfusion imaging during acute stroke interventions.